Given the lack of medical therapy available in the management of AAA, this study underscores the potential role for Lp(a)-targeted therapy in future prevention and treatment of AAA.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: Lp(a) is an independent risk factor for AAA development, distinct from other atherogenic lipoproteins such as ApoB. This evidence concerns the gene LPA and triple-A syndrome.